Immunomodulatory Effects of Human Adipose Tissue-derived Mesenchymal Stem Cells on T Cell Subsets in Patients with Rheumatoid Arthritis

  • Rasoul Baharlou Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran AND Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
  • Nesa Rashidi Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Abbas Ahmadi-Vasmehjani Department of Immunology and Microbiology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
  • Mahshid Khoubyari Department of Student Research Committee, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
  • Maryam Sheikh Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
  • Saiedeh Erfanian Research Center for Non-Communicable Diseases, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
Adipose tissue-derived mesenchymal stem cell, Foxp3, GATA3, Rheumatoid arthritis, ROR-γ, Regulatory T cells, T-bet, T helper 1, T helper 2, T helper 17


Adipose-derived mesenchymal stem cells (Ad-MSCs) have been reported to suppress the effector T cell responses and have beneficial effects on various immune disorders, like rheumatoid arthritis (RA). This study was designed to investigate the effects of co-cultured Ad-MSCs on peripheral blood mononuclear cells (PBMCs) of RA patients and healthy individuals, through assessing transcription factors of T cell subsets. PBMCs from RA patients and healthy donors were co-cultured with Ad-MSCs with or without Phytohaemagglutinin (PHA). The quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression of T-box 21 (T-bet), GATA-binding protein-3 (GATA3), retinoid-related orphan receptor γt (ROR-γt) and forkhead box P3 (Foxp3). Based on the results, Ad-MSCs greatly upregulated Th2 and Treg cell transcription factors, i.e., GATA3 and Foxp3 (p<0.05), and downregulated Th1 and Th17 transcription factors, i.e., T-bet and RORγt (p<0.05). These results demonstrate that Ad-MSCs can result in an immunosuppressive environment through inhibition of pro-inflammatory T cells and induction of T cells with a regulatory phenotype. Therefore, they might have important clinical implications for inflammatory and autoimmune diseases such as RA.


1. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. The international journal of biochemistry & cell biology. 2004;36(4):568-84.

2. Bassi G, Pacelli L, Carusone R, Zanoncello J, Krampera M. Adipose-derived stromal cells (ASCs). Transfusion and Apheresis Science.47(2):193-8.

3. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy. 2011;66(4):523-31.

4. Griffin MD, Ritter T, Mahon BP. Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies. Human Gene Therapy. 2010;21(12):1641-55.

5. Mellado M, Martínez-Muñoz L, Cascio G, Lucas P, Pablos JL, Rodríguez-Frade JM. T Cell Migration in Rheumatoid Arthritis. Frontiers in Immunology. 2015;6:384.

6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42.

7. Komatsu N, Takayanagi H. Chapter 2 - Autoimmune Arthritis: The Interface Between the Immune System and Joints. In: Frederick WA, editor. Advances in Immunology. Volume 115: Academic Press; 2012. p. 45-71.

8. Alzabin S, Williams RO. Effector T cells in rheumatoid arthritis: Lessons from animal models. FEBS Letters. 2011;585(23):3649-59.

9. Baharlou R, Ahmadi-Vasmehjani A, Faraji F, Atashzar MR, Khoubyari M, Ahi S, et al. Human adipose tissue-derived mesenchymal stem cells in rheumatoid arthritis: Regulatory effects on peripheral blood mononuclear cells activation. International immunopharmacology. 2017;47:59-69.

10. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Research & Therapy. 2005;7(2):S4.

11. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy. The Journal of Experimental Medicine. 2004;200(3):277-85.

12. Jaberipour M, Baharlou R, Hosseini A, Talei A, Razmkhah M, Ghaderi A. Increased il-17 and il-6 transcripts in peripheral blood mononuclear cells: Implication for a robust proinflammatory response in early stages of breast cancer. Middle East Journal of Cancer. 2011;2(1):19-26.

13. Ahmadi-Vasmehjani A, Baharlou R, Atashzar MR, Raofi R, Jafari M, Razavi F-S. Regulatory Effects of Estradiol on Peripheral Blood Mononuclear Cells Activation in Patients with Asthma. Iranian Journal of Allergy, Asthma and Immunology. 2018;17(1):9-17.

14. Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive Properties of Mesenchymal Stem Cells. Stem Cell Reviews and Reports. 2012;8(2):375-92.

15. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human Adipose Tissue Is a Source of Multipotent Stem Cells. Molecular Biology of the Cell. 2002;13(12):4279-95.

16. MacDonald GIA, Augello A, De Bari C. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis & Rheumatism. 2011;63(9):2547-57.

17. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815.

18. Rainsford E, Reen DJ. Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. British Journal of Haematology. 2002;116(3):702-9.

19. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009;57(11):1192-203.

20. Li FR, Wang XG, Deng CY, Qi H, Ren LL, Zhou HX. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clinical & Experimental Immunology. 2010;161(2):357-63.

21. Aksu AE, Horibe E, Sacks J, Ikeguchi R, Breitinger J, Scozio M, et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clinical Immunology. 2008;127(3):348-58.

22. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102(10):3837.

23. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90(4):516.

24. Yan Z, Zhuansun Y, Chen R, Li J, Ran P. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Experimental Cell Research. 2014;324(1):65-74.

25. Bassi ÊJ, Moraes-Vieira PMM, Moreira-Sá CSR, Almeida DC, Vieira LM, Cunha CS, et al. Immune Regulatory Properties of Allogeneic Adipose-Derived Mesenchymal Stem Cells in the Treatment of Experimental Autoimmune Diabetes. Diabetes. 2012;61(10):2534.

26. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. The Journal of experimental medicine. 2004;199(7):971-9.

27. Hashemi SM, Hassan ZM, Pourfathollah AA, Soudi S, Shafiee A, Soleimani M. Comparative immunomodulatory properties of adipose-derived mesenchymal stem cells conditioned media from BALB/c, C57BL/6, and DBA mouse strains. Journal of Cellular Biochemistry. 2013;114(4):955-65.

28. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-36.

29. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, et al. Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent Manner. The Journal of Immunology. 2009;182(10):5994-6002.

30. Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell Phenotype. The Journal of Immunology. 2010;185(1):302-12.

31. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res. 2010;20(5):510-8.

32. De Bari C. Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys? Arthritis Research & Therapy. 2015;17(1):113.

33. Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Research & Therapy. 2013;4(3):65.

34. Obermajer N, Popp FC, Soeder Y, Haarer J, Geissler EK, Schlitt HJ, et al. Conversion of Th17 into IL-17Aneg Regulatory T Cells: A Novel Mechanism in Prolonged Allograft Survival Promoted by Mesenchymal Stem Cell–Supported Minimized Immunosuppressive Therapy. The Journal of Immunology. 2014;193(10):4988-99.

35. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, et al. Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes. The Journal of Immunology. 2009;183(2):993-1004.

36. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105.

37. Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009;126(1-2):37-42.

38. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003;76(8):1208-13.

39. Crop M, Baan C, Korevaar S, Ijzermans J, Pescatori M, Stubbs A, et al. Inflammatory conditions affect gene expression and function of human adipose tissue‐derived mesenchymal stem cells. Clinical & Experimental Immunology. 2010;162(3):474-86.

40. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic Mesenchymal Stem Cells for Treatment of Experimental Autoimmune Encephalomyelitis. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2009;17(10):1799-803.

41. Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He X-L, et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. 2011;12(1):1.

How to Cite
Baharlou R, Rashidi N, Ahmadi-Vasmehjani A, Khoubyari M, Sheikh M, Erfanian S. Immunomodulatory Effects of Human Adipose Tissue-derived Mesenchymal Stem Cells on T Cell Subsets in Patients with Rheumatoid Arthritis. Iran J Allergy Asthma Immunol. 18(1):114-119.
Brief Communication